Home
Journal Information
About
Aims and Scope
Contacts and Editorial Office
Editorial Board
Editor in Chief
Publisher
Conflicts of Interest
Editorial Policies
Publication Ethics
Nickan Research Institute policy
DISCLAIMER
Open Access
Journal Issues
Current Issue
In Press
Archive
Guidelines
For Authors
For Authors-New
For Reviewers
Peer Review Process in JRIP
Peer Review Process flowchart in JRIP
Authors agreement form
Checklist for review
Editorial Workflow
Publication Ethics and Malpractice Statement
Human and animal right
Informed Consent
Create Account
Login
Please don't use dangerous characters
Title
Author
Abstract
Keywords
First Name
Last Name
Search
eISSN
:
2345-2781
Submit Your Paper
Editorial Board
Aims and Scope
Publisher
Publication Fee
Contact Us
Archive
Indexing Information
Member of
Follower of
J Renal Inj Prev
. 2016;5(2): 79-84. doi:
10.15171/jrip.2016.17
PMID:
27471739
PMCID:
PMC4962674
Original Article
Association of metabolic syndrome with serum fibroblast growth factor 21 in kidney transplanted patients
Leila Bagheri
1
, Maryam Hami
1
* , Mohammad-Javad Mojahedi
1
, Mahin Ghorban Sabbagh
1
, Hosein Ayatollahi
2
Cited by CrossRef: 4
1- Lin S, Yu L, Ni Y, He L, Weng X, Lu X, Zhang C. Fibroblast Growth Factor 21 Attenuates Diabetes-Induced Renal Fibrosis by Negatively Regulating TGF-β-p53-Smad2/3-Mediated Epithelial-to-Mesenchymal Transition via Activation of AKT.
Diabetes Metab J
. 2020;44(1):158
[Crossref]
2- Choi J, Kim J, Park I, Huh J, Kim K, Cha S, Park K, Sohn J, Park J, Koh S. Serum Fibroblast Growth Factor 21 and New-Onset Metabolic Syndrome: KoGES-ARIRANG Study.
Yonsei Med J
. 2018;59(2):287
[Crossref]
3- Goldmannová D, Spurná J, Krystyník O, Schovánek J, Cibičková L, Karásek D, Zadražil J. Adipocytokines and new onset diabetes mellitus after transplantation.
J Appl Biomed
. 2018;16(4):247
[Crossref]
4- Guo Y, Li L, Hu S. Fibroblast growth factor 21 may be a strong biomarker for renal outcomes: a meta-analysis.
Renal Failure
. 2023;45(1)
[Crossref]